Birgit Haier

715 total citations
11 papers, 556 citations indexed

About

Birgit Haier is a scholar working on Immunology, Pathology and Forensic Medicine and Rheumatology. According to data from OpenAlex, Birgit Haier has authored 11 papers receiving a total of 556 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Immunology, 4 papers in Pathology and Forensic Medicine and 4 papers in Rheumatology. Recurrent topics in Birgit Haier's work include Systemic Lupus Erythematosus Research (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Viral-associated cancers and disorders (2 papers). Birgit Haier is often cited by papers focused on Systemic Lupus Erythematosus Research (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Viral-associated cancers and disorders (2 papers). Birgit Haier collaborates with scholars based in Germany, United Kingdom and United States. Birgit Haier's co-authors include Hans Tesch, Dieter Kube, Martina Vockerodt, Volker Diehl, Peter C. Heinrich, Tahamtan Ahmadi, Iris Behrmann, Udo Holtick, Peter Buttgereit and Olivier Harari and has published in prestigious journals such as Blood, Journal of Virology and Annals of Oncology.

In The Last Decade

Birgit Haier

11 papers receiving 547 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Birgit Haier Germany 7 298 244 204 130 84 11 556
Stephanie Roberson United States 6 394 1.3× 263 1.1× 48 0.2× 118 0.9× 113 1.3× 10 626
Junjiro Tsuchiyama Japan 14 303 1.0× 271 1.1× 218 1.1× 30 0.2× 252 3.0× 30 674
M. Buonanno United States 7 479 1.6× 189 0.8× 87 0.4× 227 1.7× 49 0.6× 7 749
Jennifer Wu Taiwan 8 93 0.3× 338 1.4× 129 0.6× 68 0.5× 104 1.2× 17 639
Antonella Teramo Italy 16 402 1.3× 144 0.6× 271 1.3× 35 0.3× 99 1.2× 38 722
Paolo Fiumara Italy 12 205 0.7× 282 1.2× 303 1.5× 23 0.2× 196 2.3× 28 684
C. von Schilling Germany 11 134 0.4× 178 0.7× 185 0.9× 24 0.2× 98 1.2× 22 498
Takuya Komeno Japan 13 175 0.6× 114 0.5× 118 0.6× 36 0.3× 144 1.7× 49 595
Eri Matsuki Japan 11 132 0.4× 249 1.0× 134 0.7× 53 0.4× 61 0.7× 41 492
A. M. Liberati Italy 11 158 0.5× 127 0.5× 363 1.8× 83 0.6× 116 1.4× 20 689

Countries citing papers authored by Birgit Haier

Since Specialization
Citations

This map shows the geographic impact of Birgit Haier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Birgit Haier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Birgit Haier more than expected).

Fields of papers citing papers by Birgit Haier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Birgit Haier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Birgit Haier. The network helps show where Birgit Haier may publish in the future.

Co-authorship network of co-authors of Birgit Haier

This figure shows the co-authorship network connecting the top 25 collaborators of Birgit Haier. A scholar is included among the top collaborators of Birgit Haier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Birgit Haier. Birgit Haier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Cooper, Nichola, James B. Bussel, Maciej Kaźmierczak, et al.. (2024). Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double‐blind, placebo‐controlled phase 3 studies and their open‐label extension. British Journal of Haematology. 206(2). 675–688. 6 indexed citations
2.
Furie, Richard, Ian N Bruce, Thomas Dörner, et al.. (2021). Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Lara D. Veeken. 60(11). 5397–5407. 79 indexed citations
3.
Cleanthous, Sophie, et al.. (2021). The Patient Experience of Fatigue in Systemic Lupus Erythematosus: A Conceptual Model. Rheumatology and Therapy. 9(1). 95–108. 6 indexed citations
4.
Morel, Thomas, Stefan Cano, Susan J. Bartlett, et al.. (2021). The FATIGUE-PRO: a new patient-reported outcome instrument to quantify fatigue in patients affected by systemic lupus erythematosus. Lara D. Veeken. 61(8). 3329–3340. 4 indexed citations
5.
Furie, Richard, Ian N Bruce, Thomas Dörner, et al.. (2019). FRI0195 EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL (DZP) IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A RANDOMISED, PLACEBO (PBO)-CONTROLLED STUDY. Annals of the Rheumatic Diseases. 78. 775–776. 21 indexed citations
6.
Robak, Tadeusz, Maciej Kaźmierczak, Isidro Jarque, et al.. (2019). Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia. Blood. 134(Supplement_1). 897–897. 4 indexed citations
7.
Glatt, Sophie, Eric Helmer, Birgit Haier, et al.. (2016). First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis. British Journal of Clinical Pharmacology. 83(5). 991–1001. 114 indexed citations
8.
Vockerodt, Martina, Birgit Haier, Peter Buttgereit, Hans Tesch, & Dieter Kube. (2001). The Epstein–Barr Virus Latent Membrane Protein 1 Induces Interleukin-10 in Burkitt's Lymphoma Cells but Not in Hodgkin's Cells Involving the p38/SAPK2 Pathway. Virology. 280(2). 183–198. 76 indexed citations
9.
Kube, Dieter, Udo Holtick, Martina Vockerodt, et al.. (2001). STAT3 is constitutively activated in Hodgkin cell lines. Blood. 98(3). 762–770. 160 indexed citations
10.
Kube, Dieter, Martina Vockerodt, Olaf Weber, et al.. (1999). Expression of Epstein-Barr Virus Nuclear Antigen 1 Is Associated with Enhanced Expression of CD25 in the Hodgkin Cell Line L428. Journal of Virology. 73(2). 1630–1636. 63 indexed citations
11.
Westermann, Frank, Dieter Kube, Birgit Haier, et al.. (1996). Interleukin 10 inhibits cytokine production of human AML cells. Annals of Oncology. 7(4). 397–404. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stephanie Roberson Breakdown of academic impact, for papers by Junjiro Tsuchiyama Breakdown of academic impact, for papers by M. Buonanno Breakdown of academic impact, for papers by Jennifer Wu Breakdown of academic impact, for papers by Antonella Teramo Breakdown of academic impact, for papers by Paolo Fiumara Breakdown of academic impact, for papers by C. von Schilling Breakdown of academic impact, for papers by Takuya Komeno Breakdown of academic impact, for papers by Eri Matsuki Breakdown of academic impact, for papers by A. M. Liberati
Rankless by CCL
2026